20 results about "Corneal epithelial cell" patented technology

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

The invention belongs to the technical field of medicine preparation, and provides an ophthalmic external preparation and a preparation method thereof. According to the ophthalmic external preparation, curcumin included by hydroxypropyl-beta-cyclodextrin loaded on exosome modified by polylysine is adopted as an effective component. The preparation can improve the drug concentration of cornea tissues and realize accurate delivery of ocular surfaces; meanwhile, the exosome and curcumin form a synergistic effect, so that the release of proinflammatory factors such as IL-1beta and TNF-alpha can be inhibited, the secretion of goblet cell mucoprotein and the proliferation of corneal epithelial cells can be promoted, and the tear film rupture time is prolonged; in addition, the preparation is excellent in biocompatibility, free of ocular surface stimulation reaction and high in safety.

The invention provides a means for treating a disease involving damage of corneal epithelial cells. In particular, the invention provides a composition for use in treating a disease involving damage of corneal epithelial cells, as well as a use thereof. The composition includes (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, a pharmaceutically acceptable salt thereof, or a solvate thereof.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The application provides a method for constructing a tissue-engineered cornea based on human amniotic epithelial stem cells and application thereof, and belongs to the technical field of biotechnology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induction and differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stromal cell induction and differentiation culture medium to obtain corneal stromal cells; 2) inoculating the human corneal epithelial cell-like cells and the corneal stromal cells obtained in step 1) on the surface and inside of a decellularized corneal stromal scaffold respectively, and co-culturing for 5 days to construct a tissue-engineered cornea. The application successfully constructs a tissue-engineered cornea by inoculating two kinds of corneal cells derived from human amniotic epithelial stem cells on a human decellularized corneal stromal at the same time for the first time. In addition, the obtained corneal cells can be inoculated on various types of biomaterials such as hydrogels, thereby providing a wider application possibility for developing various types of artificial cornea products.

The present invention relates to use of a recombinant type III humanized collagen and a composition comprising the same in an eye. Provided are use of a recombinant type III humanized collagen in the preparation of a product for preventing and / or treating eye inflammation, a composition comprising the recombinant type III humanized collagen, and use of the composition in the preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant type III humanized collagen and the composition comprising the same can significantly promote the renewal and repair of corneal epithelial cells, and can also inhibit the release of inflammatory mediators, enhancing the ocular tissue barrier, enhancing tear film stability, and alleviating eye inflammation and eye dryness.

The application discloses a small-molecule active aldehyde scavenger-albumin coupled drug, a preparation method and application thereof, the coupled drug comprising a) the small-molecule active aldehyde scavenger compound or its derivative, and b) albumin, the albumin comprising at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The drug is further prepared into an ophthalmic preparation, the retention time of the drug in the cornea is improved, the efficiency of in-vitro scavenging active aldehyde is improved to 1.5 times of NS-2, the expression of inflammatory factor IL-6 of human corneal epithelial cells is significantly inhibited (greater than or equal to 50%), and the drug has no irritation to the eye. Through the long-acting sustained release of the albumin carrier and the synergistic effect of the targeted scavenging of NS, the technical defects of traditional dry eye drugs, such as short-acting and single mechanism, are overcome, and the drug has clear clinical transformation value.

Disclosed are pharmaceutical compositions for ocular administration comprising interleukin-17C (IL-17C) as protein, messenger RNA encoding IL-17C, or IL-17C protein encapsulated in a delivery vehicle. The compositions include delivery systems selected from lipid nanoparticles (LNPs), exosomes, hydrogels, and ocular inserts. In certain embodiments, the LNP formulation comprises an ionizable lipid, cholesterol, a phospholipid, and a PEG-lipid, with particles sized for ocular use; in other embodiments, exosomes derived from mesenchymal stem cells, corneal epithelial cells, or dendritic cells are loaded with IL-17C protein or IL-17C mRNA. IL-17C mRNA embodiments may include modified nucleotides and 5' cap / UTR / poly(A) features. When evaluated in relevant models, the compositions reduce alpha-SMA and collagen gel contraction, and decrease corneal opacity and neovascularization while enhancing epithelial wound closure and nerve metrics. Also disclosed is a sustained-release ocular device comprising the compositions, including hydrogel implants, bandage contact lenses, or biodegradable ocular inserts.

The invention relates to the field of medicines, in particular to a small-molecule active aldehyde scavenger compound and application thereof. The compound comprises a compound with the following structure or a derivative thereof. The compound is further prepared into an ophthalmic preparation, so that the residence time of the medicine in the cornea is prolonged, the efficiency of removing active aldehyde in vitro is improved, and the expression of a human corneal epithelial cell inflammatory factor IL-6 is remarkably inhibited. The technical defects that a traditional xerophthalmia medicine is short in effect and single in mechanism are overcome, and the obvious clinical transformation value is achieved.

The invention provides application of an STAT3 agonist ML115 in preparation of a medicine for preventing and / or treating corneal epithelium lesion, and belongs to the technical field of biological medicine preparation. The invention relates to an application of ML115 in preparation of a medicine for preventing and / or treating corneal epithelium lesion. Experiments show that diabetes can cause down-regulation of expression of STAT3 in corneal epithelium cells and delay healing of mouse corneal epithelium wounds, while addition of the STAT3 agonist ML115 can reverse the healing delay phenomenon of diabetic mouse corneal epithelium wounds and promote repair of the corneal epithelium wounds. Therefore, the technical scheme provided by the invention provides a new treatment means for repairing the corneal epithelium lesion.

The invention provides application of fludarabine in preparation of a medicine for preventing and / or treating corneal epithelium lesion, and belongs to the technical field of biological medicine preparation. The invention discloses application of fludarabine in preparation of a medicine for preventing and / or treating corneal epithelium lesion. Experiments show that diabetes can cause increase of expression of STAT1 in corneal epithelium cells and delay healing of mouse corneal epithelium wounds, and the exogenous STAT1 antagonist fludarabine can reverse the healing delay phenomenon of diabetic mouse corneal epithelium wounds and promote repair of the corneal epithelium wounds. Therefore, the technical scheme provided by the invention provides a new treatment means for repairing the corneal epithelium lesion.

This invention discloses the application of necrotizing 1 (Necrostatin-1) in the preparation of drugs for the prevention and / or treatment of dry eye, relating to the field of biomedical technology. The application of necrotizing 1 in the preparation of drugs for the prevention and / or treatment of dry eye is described. This invention is the first to discover the application of the programmed necrosis inhibitor Necrostatin-1 in the treatment of dry eye. Nec-1, by inhibiting programmed necrosis, can effectively protect corneal epithelial cells and reduce ocular surface inflammation and damage. In a scopolamine-induced dry eye model, subconjunctival injection of 0.3 μM Nec-1 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, without significant drug toxicity. Nec-1 provides a new targeting strategy for dry eye treatment and may become a potent and effective drug for the clinical treatment of dry eye in the future.

This invention provides a method for minimizing adverse effects mediated by external influences on cells, tissues, organ systems, and living organisms. [Solution] A method is provided for treating with an effective amount of a graft or block copolymer having cationic, hydrophobic, or anionic sites and hydrophilic inactivation sites. The copolymer is PLL-g-PEG. The copolymer exhibits bioadhesion through electrostatic and hydrophobic interactions, as well as inactivation by the hydrophilic sites. The copolymer is useful for reducing the viral infection rate of target cells and reducing host morbidity. The copolymer is useful for reducing toxicity associated with ADCs, including corneal epithelial toxicity. Formulations of the copolymer are safe and well tolerable. Usefulness and benefits can be obtained by treating epithelial cells and surfaces, including precursor or stem cell corneal epithelial cells, with the copolymer.

The invention provides roe polypeptide hydrogel wound dressing, a preparation method and application, and belongs to the field of wound repair medical instruments, the dressing takes roe polypeptide with the sequence of GKPVWQDLRGFY as an active ingredient and Carbomer and sodium carboxymethyl cellulose dual-network gel as a carrier matrix, the polypeptide can activate macrophages to be polarized to M2 phenotype, and the hydrogel can activate macrophages to be polarized to M2 phenotype. Expression of anti-inflammatory factors such as IL-10 and TGF-1 is up-regulated, and corneal epithelial cell migration is promoted. Animal experiments show that the dressing can significantly promote rat corneal alkali burn healing, and the healing rate reaches 71.5% within 14 days, which is 24.6% higher than that of a control group.

The peptide of the present invention has ability to bind to pituitary adenylate cyclase 1 receptor PAC1R, promotes activation of a PAC1R signaling pathway, and induces nerve cell differentiation, and thus has tear secretion promoting activity. In addition, the peptide of the present invention promotes the expression and secretion of mucoprotein of a tear component in conjunctival goblet cells, and has an activity of inhibiting inflammatory responses and cellular damage in human corneal epithelial cells. The peptide of the present invention can be used as an active substance for treating, preventing and ameliorating xerophthalmia.

This invention relates to a method for inducing corneal epithelial cells from the differentiation of pluripotent stem cells. More specifically, it relates to a method for autonomously differentiating pluripotent stem cells, such as human iPS cells, into ectodermal cell lines in a serum-free culture medium without the use of feeder cells, and then inducing the resulting ocular surface ectodermal cell lines to differentiate into corneal epithelial cells.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The antibacterial peptide provided by the invention has a remarkable inhibition effect on gram-positive bacteria such as staphylococcus aureus and enterococcus faecalis and gram-negative bacteria such as escherichia coli and acinetobacter baumannii, and the MIC value of the antibacterial peptide is 4-32 mu g / mL. Safety experiments show that under the concentration of 300 g / mL, the hemolysis rate of the antibacterial peptide is smaller than 5%; the concentration of AMP1-AMP3 is sequentially lower than 100 g / mL, 800 g / mL and 100 g / mL, the survival rate of human corneal epithelial cells is larger than 85%, toxic and side effects are small, and biocompatibility is good. Stability experiments show that the antibacterial peptide has good pH stability, thermal stability, ultraviolet irradiation stability and protease hydrolysis resistance. The antibacterial peptide provided by the invention is short in amino acid sequence, relatively low in synthesis cost, large in yield, relatively good in repeatability, high in stability and low in toxicity, and shows broad-spectrum antibacterial activity.